COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Leading International CBD Brand Gears Up to Go Public -- CFN Media29/06/2018
-   
  New Alliance Seeks to Promote Health and Prevent Illness by Addressing Social Determinants of Health in Ogden, St. George29/06/2018
-   
  News Release: Essilor and Delfin extend the deadline of the Combination Agreement - EssilorLuxottica General Meeting to be reconvened29/06/2018
-   
  Communiqué: Essilor et Delfin prolongent le terme de l'accord de rapprochement - Report de l'Assemblée Générale d'EssilorLuxottica29/06/2018
-   
  Kalytera Announces Appointment of Victoria Rudman as Interim Chief Financial Officer and Additional Payments in Shares under Payments Agreements with Salzman Group29/06/2018
-   
  BLVD Centers Posts Audited Financial Statements for Period Ending February 28, 201829/06/2018
-   
  HuMax®-AXL-ADC Progress Triggers Milestone Payment to Seattle Genetics29/06/2018
-   
  Alzheimer’s Foundation of America’s Statement on Senate Appropriations Committee Approval of FY 2019 Funding Increase for Alzheimer’s Disease Research29/06/2018
-   
  Innovation Pharmaceuticals Announces Database Lock for Phase 2b Trial of Oral Prurisol for Psoriasis29/06/2018
-   
  RavenQuest Eyes Massive Micro Cultivation Market -- CFN Media29/06/2018
-   
  Newly Public, James E. Wagner Cultivation Moves Toward Cannabis Oils -- CFN Media29/06/2018
-   
  Ultragenyx Announces Positive CHMP Opinion for Mepsevii™ (vestronidase alfa) For the Treatment of Mucopolysaccharidosis VII29/06/2018
-   
  Devonian Announces Grant of Options29/06/2018
-   
  Devonian annonce l’octroi d’options29/06/2018
-   
  Emisphere Development Update29/06/2018
-   
  Alder BioPharmaceuticals® Presents New Six-Month Data for Eptinezumab Demonstrating Improvement in Efficacy in PROMISE 2 Phase 3 Trial for Chronic Migraine29/06/2018
-   
  Alder BioPharmaceuticals® Presents New One-Year Data for Eptinezumab from PROMISE 1 Phase 3 Trial Demonstrating Long-Term Efficacy in Episodic Migraine29/06/2018
-   
  AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency29/06/2018
-   
  Tauriga Sciences Inc. Completes Initial Purchase Order with Blink Charging Co. for 4 Level II Electric Vehicle Pedestal Charging Units29/06/2018
Pages